Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jun 27;17(6):e0270554. doi: 10.1371/journal.pone.0270554

Pooled incidence and case-fatality of acute stroke in Mainland China, Hong Kong, and Macao: A systematic review and meta-analysis

Fan He 1,*, Irene Blackberry 1, Liqing Yao 2, Haiyan Xie 3, Tshepo Rasekaba 1, George Mnatzaganian 4,5
Editor: Salvatore De Rosa6
PMCID: PMC9236238  PMID: 35759497

Abstract

Background

Stroke incidence and case-fatality in Mainland China, Hong Kong, and Macao vary by geographic region and rates often differ across and within regions. This systematic review and meta-analysis (SR) estimated the pooled incidence and short-term case-fatality of acute first ever stroke in mainland China, Hong Kong, and Macao.

Methods

Longitudinal studies published in English or Chinese after 1990 were searched in PubMed/Medline, EMBASE, CINAHL, Web of Science, SinoMed and CQVIP. The incidence was expressed as Poisson means estimated as the number of events divided by time at risk. Random effect models calculated the pooled incidence and pooled case-fatality. Chi-squared trend tests evaluated change in the estimates over time. When possible, age standardised rates were calculated. Percent of variation across studies that was due to heterogeneity rather than chance was tested using the I2 statistic.The effect of covariates on heterogeneity was investigated using meta-regressions. Publication bias was tested using funnel plots and Egger’s tests.

Results

Overall, 72 studies were included. The pooled incidences of total stroke (TS), ischaemic stroke (IS) and haemorrhagic stroke (HS) were 468.9 (95% confidence interval (CI): 163.33–1346.11), 366.79 (95% CI: 129.66–1037.64) and 106.67 (95% CI: 55.96–203.33) per 100,000 person-years, respectively, varied according to the four economic regions (East Coast, Central China, Northeast and Western China) with the lowest rates detected in the East Coast. Increased trends over time in the incidence of TS and IS were observed (p<0.001 in both). One-month and three-to-twelve-month case-fatalities were 0.11 (95% CI: 0.04–0.18) and 0.15 (95% CI: 0.12–0.17), respectively for IS; and 0.36 (95% CI: 0.26–0.45) and 0.25 (95% CI: 0.18–0.32), respectively for HS. One-month case-fatality of IS and HS decreased over time for both (p<0.001). Three-to-twelve-month fatalities following IS increased over time (p<0.001). Publication bias was not found.

Conclusions

Regional differences in stroke incidence were observed with the highest rates detected in less developed regions. Although 1-month fatality following IS is decreasing, the increased trends in 3-12-month fatality may suggest an inappropriate long-term management following index hospital discharge.

Registration

Registration-URL: https://www.crd.york.ac.uk/prospero/; Reference code: CRD42020170724

Introduction

Globally, stroke is the second leading cause of death and disability after ischaemic heart disease, accounting for 11.8% of all deaths and is the third most common cause of disability worldwide [1]. Divergent trends in stroke incidence in high- and low-to-middle-income countries have been reported, showing declining and increasing incidences, respectively [2]. Predominantly cross-sectional survey data from China, the largest middle-income country with a rapidly ageing population, suggest a continuous increase in stroke incidence during recent decades [3], with first-ever stroke notifications doubling from 2002 to 2013 [4]. Within China, there are variations in stroke incidence according to a north to south divide, with highest rates in the Northeast and lowest rates in the Southeast regions [5]. Within those regions, there is considerable variation in reporting rates [6]. The pooled estimate of stroke incidence in China is unknown.

The worldwide one-month and up-to-one-year case fatality of ischaemic and haemorrhagic stroke and their temporal trends are divergent [79]. Chinese data show a steady decrease in in-hospital mortality following stroke [10], which may reflect improved immediate short-term stroke management over time due to advances in stroke treatment including thrombolysis, and patient care in acute stroke units. Trends in long term (up-to-one year) case fatality by different types of stroke in China are currently unknown. Furthermore, published stroke case-fatalities are inconsistent between and within regions [6], possibly resulting from differences in diagnostic, analytic or design methods, or selected samples that are not representative of the general Chinese population.

China has four economic regions: East Coast, Central China, Northeast and Western China. These regions were formed due to the rapid urbanisation, economic development, and change in Chinese regional population distributions over the past few decades [11]. Of these, the East Coast is the most developed while the Western region is the least developed. Incidence and case fatality of stroke by these regions are unknown. The aim of this novel systematic review and meta-analysis (SR) was to estimate the overall and regional pooled incidence of stroke and one-month and up-to-one-year case-fatality in mainland China, Hong Kong and Macao, using data from longtiduial studies and following strict inclusion and exclusion criteria. Pooled trends of different types of stroke over time were also estimated.

Methods

Search strategy and selection criteria

This SR used the World Health Organization definition of stroke ("rapidly developed clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than of vascular origin") [12]. In addition, the International Statistical Classification of Diseases and Related Health Problems codes I60-I64 (10th version) or equivalent codes in the earlier versions were utilised to identify stroke. Prospective or retrospective cohort studies on adult (aged ≥18 years) populations residing in Mainland China, Hong Kong or Macao, reported in Chinese or English and published after 1990 were eligible for inclusion. When multiple studies used the same study sample, publications with the most complete data were included. Only studies with a sample of more than 100 participants were considered; studies with fewer participants were considered as case series [13]. Studies on recurrent or prevalent stroke were excluded. Studies were also excluded when denominators for estimating the incidence were not extractable.

PubMed/Medline, EMBASE, CINAHL, and Web of Science were searched for English studies while SinoMed and CQVIP were searched for Chinese studies, published from January 1, 1990 to March 13, 2021. The title and abstract were searched for all types of acute stroke and mortality whereas, the "region", and "incidence" were searched in the full text using keywords, subject headings or MeSH terms. English and Chinese peer-reviewed articles were searched using the same strategy (S1 Table). Identified systematic reviews were further hand-searched for other potentially eligible publications. Grey literature, government reports, textbook publications, and unpublished studies were not considered. Overall, 22% of study selection and data extraction was randomly and independently reassessed. Inconsistencies in study selection were discussed in team meetings to reach consensus. If required, authors of identified papers were contacted for additional information before decisions on eligibility were reached.

Registration and protocol

The SR was registered in International Prospective Register of Systematic Reviews [registration code: CRD42020170724]. Details of the study have been reported in the study protocol [14].

Statistical analysis

Study variables included publication details, publication language, study design, type of stroke, diagnostic criteria, follow-up time, study period, regions, setting, sample size, stroke events, stroke severity (National Institutes of Health Stroke Scale and Glasgow Coma Scale), deaths, age, sex, smoking status and inclusion and exclusion criteria of the original study. Incidences of first ever total stroke, ischaemic stroke and haemorrhagic stroke were estimated as events per 100,000 person-years. Using the Exact method, the incidence rates of disease were expressed as Poisson means divided by time at risk. The log incidence rates together with their corresponding log standard errors, stratified by the four economic regions, were meta-analysed using DerSimonian and Laird random effects model. Random effects models were also used to estimate the pooled case fatality estimates. Region-specific analyses of pooled estimates of linear trends over time were assessed using a chi-squared test. The I2 statistic assessed the heterogeneity of the included studies. Since some studies excluded patients with major comorbidities, subgroup analyses were conducted according to papers that had and did not have this exclusion criterion. Funnel plots and Egger’s tests examined publication bias. Separate analyses were conducted for ischaemic, haemorrhagic, and total stroke. Meta-regressions were constructed to investigate and quantify the proportion of between-study variance explained by known study variables. The meta regression models accounted for age, sex, smoking status, severity of stroke, study setting (community or hospital), follow-up time and risk of bias.

The Newcastle-Ottawa Scale was used to assess the quality and risk of bias. The Healthcare Research and Quality standards were used to further categorise the results of Newcastle-Ottawa Scale assessments into good, fair, or poor quality. Sensitivity analyses were conducted by risk of bias.

Stata/SE 15 was used to conduct the analyses. Stata’s “metan” and “metaprop”commands were used to run the meta-analysis.

Results

A total of 41,294 English, and 46,339 Chinese publications were identified, of which, 32,355 duplicates were removed, leaving 55,278 papers for title and abstract screening. Of these, the full text of 2,440 English and 2,720 Chinese articles was examined, with 72 papers reporting incidence and/or mortality included in the final review with one study reporting both. The reporting of this SR complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Fig 1).

Fig 1. PRISMA chart, study identification.

Fig 1

Characteristics of the included publications (earliest published in 1997 and latest in 2020) are displayed in Table 1A and 1B. Studies reported on the incidences of total stroke (TS) (n = 28), haemorrhagic stroke (HS) (n = 20) and ischaemic stroke (IS) (n = 20). All except one study followed a prospective cohort design with the exception being retrospective cohort. Of the four economic regions represented in the incidence studies, the east coast was mostly represented (14 studies), followed by western China (five studies), northeast China (four studies), and central China (two studies) and nine were national. In total, the studies reporting incidence included 1,809,252 individuals contributing 13,060,309 person-years of follow-up. Both sexes were represented in most studies with just two studies focusing exclusively on either males or females. Sex was not identified in five incidence studies. The publication years of the 39 studies reporting on case-fatality [IS (n = 28 studies), HS (n = 14 studies)] ranged from 2003 to 2020. Case-fatalities of stroke patients in the East Coast were mostly reported in sixteen studies, followed by Central China (nine studies), Western China (five studies), and Northeast China (four studies). Five studies were national. Sex was not identified in eight case-fatality studies.

Table 1. a. Description of included studies: incidence.

b. Description of included studies: case-fatality.

a
Study Publication language Economic region Period of study Risk of bias Mean age % Male Sample size Type of stroke and number of cases Follow-up (person-years) Mean follow-up (years)
Du et al (1997) [15] Chinese East Coast 1979–1993 Fair 48.6 50.6 1809 35 TS, 16 HS 25212 NR
Duan et al (2019) [16] English East Coast 2010–2016 Fair 49.5 100 23433 678 TS, 595 IS, 109 HS 138255 5.9
Gu et al (2020) [17] English East Coast 2009–2014 Poor 69.1 43.8 1257 113 TS 6136 4.8
Guo et al (2013) [18] Chinese East Coast 2003–2010 Good 56.2 42.1 10565 195 TS 67886 6.4
Jia et al (2011) [19] English East Coast 2006 –NR Poor 52.9 52.8 19369 341 TS 58107 3
Li et al (2015) [20] English East Coast 1992–2012 Poor NR NR 3031 908 TS, 664 IS, 231 HS 304260 NR
Liu et al (2014) [21] English East Coast 2006–2010 Fair 51.4 79.5 90517 1472 TS, 1049 IS, 423 HS 362163 4.1
Wang et al (2016) [22] English East Coast 2002–2012 Good 56 34.8 1263 116 TS, 101 IS 11569 9.2
Wang et al (2018) [23] English East Coast 2009–2016 Fair 60.2 40.6 4081 138 IS 20040 5.2
Wang et al (2019) [24] Chinese East Coast 2005–2013 Fair NR 36.4 29689 1716 IS, 91 HS 175667 6.7
Yu et al (2016) [25] English East Coast 1996–2011 Fair 51.5 0 64328 2991 TS, 2750 IS, 241 HS 618412 10
Zhang et al (2019) [26] English East Coast 2010–2015 Fair 58.4 37.8 8500 444 TS 43350 5.1
Ji et al (2020) [27] English East Coast 2009–2017 Poor 45.7 47.8 27712 617 TS 193984 7
Wang et al (2020) [28] Chinese East Coast 2005–2013 Poor 52.1 36 28940 2164 IS, 127 HS 177279 6.2
Han et al (2017) [29] English Central 2001–2012 Fair 71.7 48.2 2852 211 TS 18628 NR
Zhou et al (2020) [30] English Central 2008–2014 Fair 61.7 44.1 31750 1557 TS, 1151 IS, 287 HS 196850 6.2
Li et al (2018) [31] English Northeast 2008 –NR Poor NR NR 1928 98 TS 9531 4.9
Sun et al (2013) [32] English Northeast 2004–2010 Fair NR NR 38949 858 TS, 483 IS, 348 HS 168023 NR
Xie et al (2019) [33] English Northeast 2012–2017 Fair 55.6 34.6 3229 81 TS 15499 4.8
Yu et al (2020) [34] English Northeast 2004–2014 Fair 50.5 NR 38589 3855 TS 275526 7.1
Guo et al (2016) [35]* English Western 2002–2012 Poor 54 52.4 425901 13274 IS, 2917 HS 1895447 NR
Olofindayo et al (2015) [36] English Western 2003–2012 Fair 46.5 40.9 2589 121 TS, 75 IS, 44 HS 23292 9.2
Ren et al (2019) [37] Chinese Western 2011–2015 Poor 46.8 61 33042 448 TS 80506 2.4
Zhang et al (2009) [38] English Western 2002–2008 Fair 64.3 45.2 2173 82 TS, 52 IS, 30 HS 9952 4.6
Zhou et al (2016) [39] Chinese Western 2011–2014 Poor NR NR 4160 51 TS 13621 3.3
Huang et al (2003) [40] Chinese National 1994–2001 Poor 54.7 51.8 24475 228 TS, 151 IS, 77 HS 105201 4.3
Huang et al (2019) [41] English National 1992–2015 Good 50.9 41 117575 2276 IS, 1019 HS 900214 NR
Kelly et al (2008) [42] English National 1991–2000 Good 55.9 49.1 155131 2421 HS 1287587 8.3
Liu et al (2008) [43] Chinese National 1992–2003 Poor 46.9 53.5 30384 613 TS, 427 IS, 159 HS 199711 NR
Wang et al (2013) [44] English National 1987–1998 Fair 51.6 47.2 26607 1108 TS, 614 IS, 451 HS 241149 NR
Zhang et al (2007) [45] Chinese National 1992 –NR Poor NR 46.4 15131 370 TS, 266 IS, 107 HS 163415 10.8
Zhou et al (2003) [46] Chinese National 1991–1997 Fair 45 48.6 9111 259 TS, 177 IS, 84 HS 131188 NR
Chen et al (2020) [47] English National 2004–2017 Fair 51.6 40.9 489586 45732 TS, 36588 IS, 8142 HS 4720000 NR
Swaminathan et al (2020) [48] English National 2003–2019 Fair 50.5 41.9 41596 1752 TS 402649 9.7
b
Study Publication language Economic region Type of stroke Period of study Risk of bias Mean age % Male Cases Deaths Follow-up
Liu et al (2018) [49] Chinese East Coast IS 2013–2017 poor 68 54.5 101 14 3 months
Shi et al (2019) [50] English East Coast IS 2010–2017 good NR NR 334 28 3 months
Geng et al (2016) [51] Chinese East Coast IS 2013–2015 fair NR NR 796 37 3 months
Fang et al (2012) [52] English East Coast IS 2003–2008 good 66.7 56.3 1184 113 28 days
Tu et al (2017) [53] English East Coast IS 2015 fair 58 54.3 737 104 3 months
Zi et al (2013) [54] English East Coast IS 2009–2012 fair 65 65.9 226 34 3 months
Chen et al (2016) [55]* English East Coast IS 2013–2015 good 68.4 58.4 871 94 3 months
Huang et al (2013) [56] English East Coast IS 2008–2011 fair 66.3 58 338 68 12 months
Liu et al (2020) [57]* Chinese East Coast IS 2012–2019 poor 72 50.4 117 20 3 months
Xi et al (2020) [58] Chinese East Coast IS 2016–2019 poor 73 54.3 138 16 3 months
Hong et al (2016) [59] Chinese East Coast IS not given fair NR NR 2479 255 3 months
2479 349 12 months
Wang et al (2018) [60]* English East Coast HS 2016–2017 fair 65.8 61.9 181 35 1 month
Wei et al (2014) [61] English East Coast HS 2010–2012 fair 69 53.1 271 34 3 months
Yan et al (2016) [62] English East Coast HS 2011–2014 poor 63.2 58.9 112 33 6 months
Jiang et al (2018) [63] Chinese East Coast HS 2016–2017 fair 63 66.3 172 12 30 days
Hu et al (2012) [64] English East Coast HS 2011 fair 63.1 61.4 176 64 3 months
Nie et al (2017) [65] English Central IS 2013–2016 fair 59 53 387 74 12 months
Wang et al (2014) [66] English Central IS 2011–2014 fair 68 50.9 275 75 12 months
Zhu et al (2018) [67] English Central IS 2016–2017 fair 66 48.2 299 31 3 months
Jing et al (2019) [68] English Central IS 2016–2018 fair 65 58.2 196 43 12 months
Sun et al (2015) [69] English Central IS 2004–2010 good NR NR 790 73 30 days
790 116 12 months
Lin et al (2014) [70] Chinese Central HS 2010–2012 fair 58.2 62.9 167 58 6 months
Zhang et al (2014) [71]* English Central HS 2007–2013 poor 72.6 59.3 118 50 1 month
Yang et al (2004) [72] English Central HS not given poor 69.7 NR 722 407 28 days
Jiang et al (2011) [73] Chinese Central HS 2009–2010 fair 61.5 55.5 182 57 30 days
Wang et al (2014) [74] English Northeast IS 2012–2013 fair 65 60.4 326 38 1 month
Dong et al (2013) [75] English Northeast IS 2010–2011 poor 69 55.2 125 18 3 months
Zhang et al (2013) [76] English Northeast IS 2007–2011 fair 72 58 245 41 12 months
Xie et al (2016) [77] English Northeast IS 2013–2014 fair 61 64.8 216 32 6 months
Du et al (2018) [78] Chinese Western IS 2013–2017 poor 70.8 55.7 122 34 3 months
Zhang et al (2007) [79]* English Western IS 2000–2006 fair NR NR 1904 327 1 month
Tao et al (2017) [80] English Western HS 2010–2013 fair 58.5 64.3 336 90 3 months
He et al (2018) [81] English Western HS 2015–2016 fair NR NR 221 47 3 months
Li et al (2008) [82] English Western IS not given fair 65.5 57 395 32 3 months
HS not given 65.5 57 254 39 3 months
Wu et al (2014) [83] English Nation wide IS 2007–2010 fair 63 64.9 1229 144 12 months
Tu et al (2017) [84] English Nation wide IS 2012–2015 fair 68 54.4 4215 906 12 months
Tu et al (2019) [85] English Nation wide IS 2015–2017 fair 65 52 1530 325 6 months
Zhang et al (2003) [86] English Nation wide IS 1991–2000 good NR NR 6772 1144 28 days
HS 1991–2000 NR NR 3489 1691 28 days
Chen et al (2020) [47] English Nation wide IS 2004–2017 fair 59.3 44.8 36588 1098 28 days
59.3 44.8 36588 2267 12 months
HS 2004–2017 fair 59.3 51.3 8142 3630 28 days

Notes

*Studies marked with asterisk followed a retrospective design, while others were prospective cohort.

†Four economic regions: East Coast (Beijing, Tianjin, Hebei, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, Guangdong and Hainan); Central (Shanxi, Anhui, Jiangxi, Henan, Hubei and Hunan); Northeast (Liaoning, Jilin and Heilongjiang); Western (Inner Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, Gansu, Qinghai, Ningxia and Xinjiang)

Abbreviation: Not reported (NR)

Of the 34 studies reporting incidence, 22 (65%) were classified as having good to moderate quality while 12 (35%) were deemed poor quality. The 39 papers reporting case-fatality included 31 (79%) with good to fair quality while 8 (21%) were rated as poor. The quality assessment details can be found in S2 Table. The percentage of agreement among co-authors (FH, HX, TR, GM) and collaborators (YZ, YH, ZP, SL, RY) conducting the culling and quality assessments ranged from 88% to 95%, with the corresponding Cohen Kappa values ranging from 0.48 to 0.56. The overall percentage of agreement was 92%, Cohen Kappa 0.51 [95% confidence interval (CI): 0.45–0.58].

Geographical differences in the pooled incidences of total stroke were found with the highest being in Central China (887.87 per 100,000 person-years) and the lowest in the East Coast region (409.34 per 100,000 person-years). The overall incidence was 468.90 (95% CI: 163.33–1346.11) per 100,000 person-years (Fig 2), increasing to 541.01(95% CI: 149.51–1957.68) per 100, 000 person-years when poor quality studies were excluded from the analysis. The combined pooled estimate in Central, Northeast and Western China of 698.52 (95% CI: 74.87–6517.18) per 100,000 person-years was significantly higher than that in the East Coast region (409.34 (95% CI: 73.22–2288.38)), p<0.001 (S1 Fig).

Fig 2. Total stroke incidence rate per 100,000 person-years.

Fig 2

Similar regional differences were detected for both ischaemic and haemorrhagic stroke when comparing overall pooled estimates for Central, Northeast and Western China with the East Coast region. For IS the pooled estimate of 505.26 (95% CI: 49.47–5160.46) compared to 438.33 (95% CI: 66.01–2910.54) per 100,000 person-years for the East Coast Region while, for HS, the pooled estimate of 165.08 (95% CI: 31.91–854.01) compared to 57.41 (95% CI: 18.24–180.65) per 100,000 person-years for the East Coast region (S2 and S3 Figs). No between-studies heterogeneity was detected in all types of stroke and no publication bias was found as shown in S4 Fig. Egger’s tests p values for TS, IS and HS were p = 0.17, p = 0.39, and p = 0.43, respectively. The regional differences observed in the sensitivity analysis were consistent with our main findings (S5 Fig). Age standardisation was limited to a few selected studies based on data availability resulting in an estimated age standardised incidence for TS, IS, and HS of 285.76 (95% CI: 29.37–2780.33), 586.76 (95% CI: 7.05–48813.46) and 141.55 (95% CI: 4.58–4379.29) per 100, 000 person-years, respectively.

Fig 3 shows the scatter plots for stroke incidence using the median study period year for each study. Studies published in a period of four consecutive years were pooled together, starting from the latest year. The analyses showed a statistically significant increase over time in total stroke, ischaemic stroke and haemorrhagic stroke (Chi-squared test p value<0.001 in all).

Fig 3. Scatter plots of stroke incidence by median study period.

Fig 3

Subgroup analyses were based on initial study sample selection criteria. Studies that included a more representative sample (without the exclusion of patients with major comorbidities such as coronary heart disease) were categorised as group one. Studies that used selected samples, often only including healthier individuals, which made the samples less representative of the general Chinese population, were categorised as group two. Pooled incidence of TS in the more representative sample was slightly higher than that found in group two, 474.09 (95% CI: 38.47–5842.50) per 100,000 person-years versus 467.79 (95% CI: 146.36–1495.20) (S6 Fig).

The pooled estimates of one-month and three-to-twelve-month case-fatality were 0.11 (95% CI: 0.04–0.18) and 0.15 (95% CI: 0.12–0.17), respectively for IS; and 0.36 (95% CI: 0.26–0.45) and 0.25 (95% CI: 0.18–0.32), respectively for HS (Figs 4 and 5). Excluding studies with poor quality produced similar findings. High between-study heterogeneity was found when studies were stratified by follow-up time (I2 >90%). Based on meta-regressions, risk of bias, study setting (community or hospital), and follow-up time explained between 11.4% to 17.4% of between-study variance in IS. For HS, risk of bias, study setting, and smoking status explained between 51.7% to 73.5% of between-study variance. Mean age, sex, and severity of stroke did not contribute to study heterogeneity in either type of stroke.

Fig 4. Pooled case-fatalities of ischaemic stroke.

Fig 4

Fig 5. Pooled case-fatalities of haemorrhagic stroke.

Fig 5

Following the same method used in subgroup analysis of stroke incidence, one-month estimates of IS were similar in both groups. However, these varied for HS with pooled estimates being higher in the more representative sample [0.49 (95% CI: 0.44–0.55) versus 0.25 (95% CI: 0.10–0.40)] in the less representative group.

The scatter plots of case-fatality of IS and HS using the median study period year for each study are shown in Fig 6. Decreased trends in 1-month IS and HS case-fatality were detected (p<0.001 in both), whereas, 3-12-month IS case-fatality increased over time (p<0.001). Trends in 3-12-month HS case fatality could not be investigated due to limited points in time (n = 3) after studies were pooled by median years.

Fig 6. Scatter plots of stroke case-fatality by median study period.

Fig 6

Discussion

This is the first study to report pooled estimates of incidence and case-fatality of stroke in China using data from longitudinal cohort studies. Our estimated figures support previous findings that China has one of the highest rates of stroke incidence in the world [87]. We report significant differences in incidences of TS, IS and HS between the East Coast (with lowest rates) and other economic regions (with higher rates) in China. This SR reports that although 1-month fatality following ischaemic stroke has decreased over the past decades, 3-12-month mortality following the event has significantly increased during this time.

Rates of stroke incidence rates are often reported inconsistently in China [6]. Such inconsistensies in reportings may have resulted from different diagnostic and definitional criteria [6], and different study designs including door-to-door surveys that lack follow-up periods and potentially generate biased estimates due to sampling errors, non-response and reporting bias [88]. As detected in our SR, studies reporting stroke incidence have often excluded patients with histories of certain comorbidities [27], making the sample less representative of the general Chinese population at risk of stroke. Regional differences in stroke incidence may also be explained by the different patterns of risk factors reported across China. For instance, the higher prevalence of hypertension in Northern, Northeast and Central China may have contributed to a higher incidence of stroke [3]. The disparities in stroke incidence among the four economic regions, identified in this SR, highlight the need for primary stroke prevention, health promotion, and better access to health services in less-developed regions.

Consistent with previous research [4], this SR reports an increased incidence of TS, IS and HS over time, which is consistent with findings from other low to middle countries that are experiencing a similar trend [2]. As a result of rapid economic development, there is evidence to indicate that populations living in different parts of China have changed their lifestyle, their diet (consuming more fast foods), and have become less physically active [89]. This may have led to higher rates of obesity, hypertension and diabetes, which in turn can lead to higher rates of stroke [90]. The increase in incidence may also be explained by the rapidly aging population or improvements in stroke diagnosis [4, 91]. In contrast, stroke incidence in high income countries significantly declined from 1990 to 2010 [2]. This may indicate that China lags behind in stroke prevention despite the rapid economic growth experienced in the same period.

This SR reports decreasing trends in one-month IS and HS case-fatality, consistent with a previous study that reported decreased in-hospital mortality for all types of stroke [10]. Underlying factors contributing to the downward trend in short-term stroke case-fatality in China may include improved treatments, expanded healthcare coverage, enhanced preventative campaigns and increased public health literacy around stroke [92]. This study, however, also found an opposing increase in 3-12-month IS case-fatality, which may indicate a need to improve secondary prevention, post-stroke rehabilitation and support for caregivers, especially for those discharged from acute care. This is supported by a study that found that Chinese stroke patients were less likely to adhere to antiplatelet and lipid lowering therapy after 3 months post discharge, with a large proportion of these patients not filling prescriptions or refusing to take prescribed medications [93]. Barriers for patients to adhere to post-stroke medication regimens include limited health literacy, inadequate communication and poor coordination between medical staff and patients, and cost [94]. Although recommended by guidelines, a national study reported that around 40% of IS patients were not properly rehabilitated with rehabilitation services varying across hospitals [95]. Underlying reasons for such suboptimal stroke rehabilitation may include lack of insurance coverage, absence of well-established rehabilitation systems, a lack of trained and licensed therapists and caregivers, and limited availability of rehabilitation technologies [96]. Furthermore, due to the barriers to accessing government-funded services, post-stroke patient care often falls on family members who lack medical skills and have little social support to properly manage discharged patients at home [97, 98].

This SR highlights the need to tackle inequality in stroke prevention across the four economic regions by reinforcing and concretising policies. This SR also emphasises the need to establish well-coordinated rehabilitation system programs that will meet the needs of individuals coming from different socioeconomic backgrounds.

Strengths and limitations

The comprehensive search strategy targeted six major electronic databases to identify potentially eligible English and Chinese articles. The earliest publication year was restricted to 1990 since brain imaging technologies were widely used after this year in China [99], which made the case ascertainment of stroke more reliable. The restriction to 1991 onwards aimed to decrease false positives and to increase the validity of included cases. Our strict selection criteria, that included longitudinal studies with a defined follow-up period, ensured the inclusion of only acute first-ever stroke. This study, covering a time period of four decades (1979 to 2019), included around 2 million participants of all ages and over 13 million person-years of follow-up.

This SR also has limitations. Less developed regions were under-represented which may indicate that the regional differences we found could, in reality, be greater. The age-standardised rates were mostly based on studies from the East Coast, which had lower estimates than other regions. This may explain the large differences in the crude and age-standardised rates. Duplicate research populations were carefully screened for using all available information with papers reporting on the same study population included once. There may, however, have been some overlap in study populations from the same region in studies which included limited descriptions of participants. Subtypes of IS and HS were not evaluated in this SR. The sources of heterogeneity investigated in our study were limited to available variables reported in the included studies.

Conclusions

The disparities in stroke incidence between economically developed regions and less developed regions necessinate decision-making and action to address inequalities in stroke education and prevention across China. The rising trends in 3-12-month case-fatality following ischemic stroke highlight the need to develop more effective secondary stroke prevention programs, including higher adherence to antiplatelet and lipid lowering therapies and improvement of post stroke rehabilitation.

Supporting information

S1 Checklist. PRISMA checklist.

(DOCX)

S1 Table. Search strategy.

(DOCX)

S2 Table. Risk of bias assessments.

(DOCX)

S1 Fig. Pooled estimates of total stroke incidence in east coast China and other regions.

(TIFF)

S2 Fig. Pooled estimates of ischaemic stroke incidence in east coast China and other regions.

(TIFF)

S3 Fig. Pooled estimates of haemorrhagic stroke incidence in east coast China and other regions.

(TIFF)

S4 Fig. Funnel plots and Egger’s tests.

(TIFF)

S5 Fig. Sensitivity analysis for total stroke incidence.

(TIFF)

S6 Fig. Total stroke incidence rate by sub-group analysis.

(TIFF)

S7 Fig. Pooled estimates of total stroke incidence in map of China.

(TIFF)

S8 Fig. Total stroke incidence by length of follow up.

(TIFF)

S9 Fig. Pooled estimates of ischaemic stroke incidence by the four Chinese economical regions.

(TIFF)

S10 Fig. Pooled estimates of haemorrhagic stroke incidence by the four Chinese economical regions.

(TIFF)

S1 File. Included Chinese papers and translations.

(DOCX)

Acknowledgments

This study was conceived and designed by FH, GM and IB. Search strategy was developed by FH, GM, LY and HX. Articles selection and data extraction were conducted by FH, GM, TR and HX. Data analysis were run, and results were interpreted by FH and GM. Manuscript was drafted by FH, GM, reviewed and approved by all authors.

We thank Ms Ying Zhao, Ms Ying He, Mr Zhipeng Pan, Mr Sicheng Li and Ms Ruihong Yao for their contribution in study selection. We thank Dr Sean MacDermott for proofreading the final version of the manuscript.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

GM received 2020 China Studies Seed-funding Research Grant Scheme from La Trobe University (https://www.latrobe.edu.au/) for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120:439–448. doi: 10.1161/CIRCRESAHA.116.308413 [DOI] [PubMed] [Google Scholar]
  • 2.Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. The Lancet. 2014;383:245–255. doi: 10.1016/s0140-6736(13)61953-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017;135:759–771. doi: 10.1161/CIRCULATIONAHA.116.025250 [DOI] [PubMed] [Google Scholar]
  • 4.Guan T, Ma J, Li M, Xue T, Lan Z, Guo J, et al. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology. 2017;89:53–61. doi: 10.1212/WNL.0000000000004056 [DOI] [PubMed] [Google Scholar]
  • 5.Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16:203–212. doi: 10.1038/s41569-018-0119-4 [DOI] [PubMed] [Google Scholar]
  • 6.Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet neurol. 2007;6:456–464. doi: 10.1016/S1474-4422(07)70004-2 [DOI] [PubMed] [Google Scholar]
  • 7.Zhang R, Wang Y, Fang J, Yu M, Wang Y, Liu G. Worldwide 1-month case fatality of ischaemic stroke and the temporal trend. Stroke Vasc Neurol. 2020;5:353–360. doi: 10.1136/svn-2020-000371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gabet A, Grimaud O, de Peretti C, Béjot Y, Olié V. Determinants of Case Fatality After Hospitalization for Stroke in France 2010 to 2015. Stroke. 2019;50:305–312. doi: 10.1161/STROKEAHA.118.023495 [DOI] [PubMed] [Google Scholar]
  • 9.Carlsson M, Wilsgaard T, Johnsen SH, Vangen-Lønne AM, Løchen M-L, Njølstad I, et al. Temporal Trends in Incidence and Case Fatality of Intracerebral Hemorrhage: The Tromsø Study 1995–2012. Cerebrovasc Dis Extra. 2016;6:40–49. doi: 10.1159/000447719 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.He Q, Wu C, Luo H, Wang Z, Ma X, Zhao Y, et al. Trends in In-Hospital Mortality among Patients with Stroke in China. Plos One. 2014;9. doi: 10.1371/journal.pone.0092763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Li M, He B, Guo R, Li Y, Chen Y, Fan Y. Study on population distribution pattern at the county level of China. Sustainability. 2018;10:3598. [Google Scholar]
  • 12.Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58:113. [PMC free article] [PubMed] [Google Scholar]
  • 13.Abu-Zidan FM, Abbas AK, Hefny AF. Clinical "case series": a concept analysis. Afr Health Sci. 2012;12:557–562. [PMC free article] [PubMed] [Google Scholar]
  • 14.He F, Blackberry I, Yao L, Xie H, Mnatzaganian G. Geographical Disparities in Pooled Stroke Incidence and Case Fatality in Mainland China, Hong Kong, and Macao: Protocol for a Systematic Review and Meta-analysis. JMIR Res Protoc. 2022. Jan 18;11(1):e32566. doi: 10.2196/32566 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Du F, Wang H, Zhu J, Zhang S, Qian W, Wang Z, et al. Factors influencing the different incidences between coronary heart disease and storke. Chin J Cardiol. 1997;25:16–19. [Google Scholar]
  • 16.Duan Y, Wang A, Wang Y, Wang X, Chen S, Zhao Q, et al. Cumulative alcohol consumption and stroke risk in men. J Neurol. 2019;266:2112–2119. doi: 10.1007/s00415-019-09361-6 [DOI] [PubMed] [Google Scholar]
  • 17.Gu X, Fang X, Ji X, Tang Z, Wang C, Guan S, et al. Kidney dysfunction is associated with risk of cardiovascular events in middle-aged and elderly population with hypertension: A 5-year community-based cohort study in China. Clin Nephrol. 2020;93:130–139. doi: 10.5414/CN109712 [DOI] [PubMed] [Google Scholar]
  • 18.Guo J, Huang J, Guan Y, Chen H, Yang Y, Tao Y, et al. A cohort study on the relationship between cerebrovascular hemodynamic changing and risk of stroke. Chin J Prev Med. 2013;323–327. [PubMed] [Google Scholar]
  • 19.Jia Z, Wu S, Zhou Y, Wang W, Liu X, Wang L, et al. Metabolic syndrome and its components as predictors of stroke in middle-aged and elderly Chinese people. Neurol Res. 2011;33:453–459. doi: 10.1179/016164111X13007856083882 [DOI] [PubMed] [Google Scholar]
  • 20.Li B, Lou Y, Gu H, Long X, Wang T, Wei J, et al. Trends in incidence of stroke and transition of stroke subtypes in rural Tianjin China: A population-based study from 1992 to 2012. Plos One.2015; 10:e0139461. doi: 10.1371/journal.pone.0139461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Liu Y, Wang J, Zhang L, Wang C, Wu J, Zhou Y, et al. Relationship between C-reactive protein and stroke: a large prospective community based study. Plos One. 2014;9:e107017. doi: 10.1371/journal.pone.0107017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wang H, Laskowitz DT, Dodds JA, Xie G, Zhang P, Huang Y, et al. Peak Systolic Velocity Measurements with Transcranial Doppler Ultrasound Is a Predictor of Incident Stroke among the General Population in China. Plos One. 2016;11:e0160967. doi: 10.1371/journal.pone.0160967 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang W, Shen C, Zhao H, Tang W, Yang S, Li J, et al. A prospective study of the hypertriglyceridemic waist phenotype and risk of incident ischemic stroke in a Chinese rural population. Acta Neurol Scand. 2018;138:156–162. doi: 10.1111/ane.12925 [DOI] [PubMed] [Google Scholar]
  • 24.Wang X, Hu X, Guo Y, Bian Z, Li L, Chen Z, et al. Relationship between hypertension and cardiovascular and cerebrovascular diseases among adult residents in Hainan province: a prospective cohort study. Chin J Public Health. 2019;035:986–991. [Google Scholar]
  • 25.Yu D, Zhang X, Shu X, Cai H, Li H, Ding D, et al. Dietary glycemic index, glycemic load, and refined carbohydrates are associated with risk of stroke: a prospective cohort study in urban Chinese women. Am J Clin Nutr. 2016;104:1345–1351. doi: 10.3945/ajcn.115.129379 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhang J, Du R, Peng K, Wu X, Hu C, Li M, et al. Serum lipoprotein (a) is associated with increased risk of stroke in Chinese adults: A prospective study. Atherosclerosis. 2019;289:8–13. doi: 10.1016/j.atherosclerosis.2019.07.025 [DOI] [PubMed] [Google Scholar]
  • 27.Ji A, Lou H, Lou P, Xu C, Zhang P, Qiao C, et al. Interactive effect of sleep duration and sleep quality on risk of stroke: An 8-year follow-up study in China. Sci Rep. 2020;10:8690. doi: 10.1038/s41598-020-65611-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wang X, Hu X, Guo Y, Bian Z, Li L, Chen Z, et al. Prospective study on tobacco smoking and the risk of cardiovascular disease among adults in Hainan Province. Modern Prevent Med. 2020;47:287–299. [Google Scholar]
  • 29.Han T, Wang H, Wei L, Pan Y, Ma Y, Wang Y, et al. Impacts of undetected and inadequately treated hypertension on incident stroke in China. BMJ open. 2017;7:e016581. doi: 10.1136/bmjopen-2017-016581 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhou L, Yu K, Yang L, Wang H, Xiao Y, Qiu G, et al. Sleep duration, midday napping, and sleep quality and incident stroke The Dongfeng-Tongji cohort. Neurology. 2020;94:e345–e356. doi: 10.1212/WNL.0000000000008739 [DOI] [PubMed] [Google Scholar]
  • 31.Li X, Pang X, Liu Z, Zhang Q, Sun C, Yang J, et al. Joint effect of less than 1 h of daytime napping and seven to 8 h of night sleep on the risk of stroke. Sleep Med. 2018;52:180–187. doi: 10.1016/j.sleep.2018.05.011 [DOI] [PubMed] [Google Scholar]
  • 32.Sun Z, Zheng L, Detrano R, Zhang X, Li J, Hu D, et al. An epidemiological survey of stroke among rural Chinese adults results from the Liaoning province. Int J Stroke. 2013;8:701–706. doi: 10.1111/j.1747-4949.2012.00897.x [DOI] [PubMed] [Google Scholar]
  • 33.Xie Y, Ma M, Li Z, Guo X, Sun G, Sun Z, et al. Elevated blood pressure level based on 2017 ACC/AHA guideline in relation to stroke risk in rural areas of Liaoning province. BMC Cardiovasc Disord. 2019;19:258. doi: 10.1186/s12872-019-1197-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yu B, Jin S, Wang C, Yan S, Zhou X, Cui X, et al. The association of outdoor temperature with blood pressure, and its influence on future cardio-cerebrovascular disease risk in cold areas. J Hypertens. 2020;38:1080–1089. doi: 10.1097/HJH.0000000000002387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Guo Y, Wang H, Tao T, Tian Y, Wang Y, Chen Y, et al. Determinants and time trends for ischaemic and haemorrhagic stroke in a large Chinese population. Plos One. 2016;11:e0163171. doi: 10.1371/journal.pone.0163171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Olofindayo J, Peng H, Liu Y, Li H, Zhang M, Wang A, et al. The interactive effect of diabetes and central obesity on stroke: A prospective cohort study of inner Mongolians. BMC Neurol. 2015;15:65. doi: 10.1186/s12883-015-0328-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ren X, Shi D, Zhang D, Ding J, Li H, Gan T, et al. Prospective study of relationship between metabolic diseases and stroke in Jinchang Cohort. Chin J Epidemiol. 2019;40:521–525. doi: 10.3760/cma.j.issn.0254-6450.2019.05.006 [DOI] [PubMed] [Google Scholar]
  • 38.Zhang W, Liu C, Wang Y, Xu Z, Chen Y, Zhou H. Metabolic syndrome increases the risk of stroke: a 5-year follow-up study in a Chinese population. J Neurol. 2009;256:1493–1499. doi: 10.1007/s00415-009-5150-2 [DOI] [PubMed] [Google Scholar]
  • 39.Zhou W, Peng N, Shi L, Zhang Q, Hu Y, Xu S, et al. Analysis of the correlation between the change of ABI and new adverse cardiovascular events. Tianjin Med J. 2016;44:959–962. [Google Scholar]
  • 40.Huang J, Wang G, Shen F, Cao Y, Wang Y, Guo Z, et al. A cohort study on cerebral vascular hemodynamics accumulative score and risks of stroke. Chin J Epidemiol. 2003;24:89–93. [PubMed] [Google Scholar]
  • 41.Huang K, Liang F, Yang X, Liu F, Li J, Xiao Q, et al. Long term exposure to ambient fine particulate matter and incidence of stroke: prospective cohort study from the China-PAR project. Bmj. 2019;367:l6720. doi: 10.1136/bmj.l6720 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kelly TN, Gu D, Chen J, Huang J, Chen J, Duan X, et al. Cigarette smoking and risk of stroke in the Chinese adult population. Stroke. 2008;39:1688–1693. doi: 10.1161/STROKEAHA.107.505305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Liu Q, Zhao D, Wang W, Liu J, Sun J, Liu J. A prospective study of serum high density lipoprotein cholesterol, cardiovascular and cerebrovascular risk in a Chinese muti-provinces cohort. Chin J Intern Med. 2008;47:272–276. [PubMed] [Google Scholar]
  • 44.Wang C, Liu Y, Yang Q, Dai X, Wu S, Wang W, et al. Body mass index and risk of total and type-specific stroke in Chinese adults: Results from a longitudinal study in China. Int J Stroke. 2013;8:245–250. doi: 10.1111/j.1747-4949.2012.00830.x [DOI] [PubMed] [Google Scholar]
  • 45.Zhang L, Wu Y, Li Y, Li X, Xie G, Zhao L. A cohort study on parentaI history and risk factors of stroke in Chinese population. Chin J Epidemiol. 2007;28:1060–1063. [PubMed] [Google Scholar]
  • 46.Zhou B, Liu X, Wu Y, Li Y, Li Y, Mai J, et al. Predictive value of diabetes and impaired fasting glucose to incidence of cardiovascular disease in middle-aged Chinese. Chin J Cardiol. 2003;31:226–230. [Google Scholar]
  • 47.Chen Y, Wright N, Guo Yu, Turnbull I, Kartsonaki C, Yang L, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0·5 million Chinese adults. Lancet Glob Health. 2020;8:e580–e590. doi: 10.1016/S2214-109X(20)30069-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Swaminathan S, Dehghan M, Raj JM, Thomas T, Rangarajan S, Jenkins D, et al. Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. Bmj. 2021;372:m4948. doi: 10.1136/bmj.m4948 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Liu Y, Zhang M, Gao P, Zhang Z, Zhou X, Yun W. Influence of intravenous thrombolysis on prognosis of acute ischemic stroke in patients with moderate to severe leukoaraiosis. Natl Med J China. 2018;98:998–1002. doi: 10.3760/cma.j.issn.0376-2491.2018.13.009 [DOI] [PubMed] [Google Scholar]
  • 50.Shi J, Liu Y, Liu Y, Liu H, Xu J, Zhang X, et al. Dynamic Changes in the Estimated Glomerular Filtration Rate Predict All-Cause Mortality After Intravenous Thrombolysis in Stroke Patients. Neurotox Res. 2019;35:441–450. doi: 10.1007/s12640-018-9970-7 [DOI] [PubMed] [Google Scholar]
  • 51.Geng S, Liu N, Meng P, Ji N, Sun Y, Xu Y, et al. Correlation between blood pressure variability and cognitive impairment in patients with acute ischemic stroke. Int J Cerebrovasc Dis. 2016;24:992–997. [Google Scholar]
  • 52.Fang X, Wang W, Zhang X, Liu H, Zhang H, Qin X, et al. Incidence and survival of symptomatic lacunar infarction in a Beijing population: a 6-year prospective study. Eur J Neurol. 2012;19:1114–1120. doi: 10.1111/j.1468-1331.2012.03709.x [DOI] [PubMed] [Google Scholar]
  • 53.Tu W, Zeng X, Deng A, Zhao S, Luo D, Ma G, et al. Circulating FABP4 (Fatty Acid-Binding Protein 4) Is a Novel Prognostic Biomarker in Patients With Acute Ischemic Stroke. Stroke. 2017;48:1531–1538. doi: 10.1161/STROKEAHA.117.017128 [DOI] [PubMed] [Google Scholar]
  • 54.Zi W, Shuai J. Cortisol as a prognostic marker of short-term outcome in chinese patients with acute ischemic stroke. Plos One. 2013;8:e72758. doi: 10.1371/journal.pone.0072758 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 55.Chen L, Xu J, Sun H, Wu H, Zhang J. The total cholesterol to high‐density lipoprotein cholesterol as a predictor of poor outcomes in a Chinese population with acute ischaemic stroke. J Clin Lab Anal. 2017;31:e22139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Huang J, Hu J, Chen N, Hu M. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit Care. 2013;28:792–797. doi: 10.1016/j.jcrc.2012.10.003 [DOI] [PubMed] [Google Scholar]
  • 57.Liu Y, Zhan Y, Pan H, Yin J, Hu Y, Cai X, et al. Comparison of outcomes after thrombectomy in patients with embolic stroke of undetermined source and cardiogenic stroke. Journal of shanghai jiao tong university (medical science). 2020;40:1271–1276. [Google Scholar]
  • 58.Xi H, Wu Q, Chen Ke. Influence of intravenous rt-PA thrombolysis and its timing selection on prognosis of elderly acute ischaemic stroke patient with comorbid atrial fibrillation. Chinese Journal of Gerontology. 2020;40:2491–2494. [Google Scholar]
  • 59.Hong Y, An Z. Three-year follow-up of 2479 registered ischemic stroke patients. Chin J Geriatr Heart Brain Vessel Dis.2016;18:59–63. [Google Scholar]
  • 60.Wang F, Wang L, Jiang T, Xia J, Xu F, Shen L, et al. Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor of 30-Day Mortality of Intracerebral Hemorrhage Patients: a Validation Cohort Study. Neurotox Res. 2018;34:347–352. doi: 10.1007/s12640-018-9890-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Wei Z, Ou Y, Li X, Li H. The 90-day prognostic value of copeptin in acute intracerebral hemorrhage. Neurol Sci. 2014;35:1673–1679. doi: 10.1007/s10072-014-1809-2 [DOI] [PubMed] [Google Scholar]
  • 62.Yan X, Yu G, Jie Y, Fan X, Huang Q, Dai W. Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. J Neurol Sci. 2016;368:121–127. doi: 10.1016/j.jns.2016.06.071 [DOI] [PubMed] [Google Scholar]
  • 63.Jiang M, Gu S, Cai N, Liu Y, Zhang Q, Wang J, et al. Predictive value of the neutrophil-to-lymphocyte ratio in the clinical prognosis of patients with acute intracerebral hemorrhage. Chin J Crit Care Dec. 2018;38:1057–1061. [Google Scholar]
  • 64.Hu H, Xiao F, Yan Y, Wen S, Zhang L. The prognostic value of serum tau in patients with intracerebral hemorrhage. Clin Biochem. 2012;45:1320–1324. doi: 10.1016/j.clinbiochem.2012.06.003 [DOI] [PubMed] [Google Scholar]
  • 65.Nie Z, Ji X, Wang J, Zhang H. Serum levels of 25-hydroxyvitamin D predicts infarct volume and mortality in ischemic stroke patients. J Neuroimmunol. 2017;313:41–45. doi: 10.1016/j.jneuroim.2017.10.002 [DOI] [PubMed] [Google Scholar]
  • 66.Wang C, Wang J, Zhang Y, Li Q, Guo S, Ji S. Plasma levels of copeptin predict 1-year mortality in patients with acute ischemic stroke. Neuroreport. 2014;25:1447–1452. doi: 10.1097/WNR.0000000000000290 [DOI] [PubMed] [Google Scholar]
  • 67.Zhu Y, Zhang J, Liu L, Han Y, Ge X, Zhao S. Evaluation of serum retinol-binding protein-4 levels as a biomarker of poor short-term prognosis in ischemic stroke. Biosci Rep. 2018;38. doi: 10.1042/BSR20180786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Jing Y, Yue X, Yang S, Li S. Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. J Nutr Health Aging. 2019;23:266–270. doi: 10.1007/s12603-019-1168-z [DOI] [PubMed] [Google Scholar]
  • 69.Sun X, Wang T, Zhang N, Yang Q, Lu Y. Incidence and survival of lacunar infarction in a southern Chinese population: A 7-year prospective study. Brain Inj. 2015;29:739–744. doi: 10.3109/02699052.2015.1004752 [DOI] [PubMed] [Google Scholar]
  • 70.Lin C, Wang Q, Ai W. Prospective study on clinical characteristics of intraventricular hemorrhage and risk factors of its prognosis. Chin J Nerv Ment Dis. 2014;40:694–697. [Google Scholar]
  • 71.Zhang J, Wang L, Xiong Z, Han Q, Du Q, Sun S, et al. A treatment option for severe cerebellar hemorrhage with ventricular extension in elderly patients: intraventricular fibrinolysis. J Neurol. 2014;261:324–329. doi: 10.1007/s00415-013-7198-2 [DOI] [PubMed] [Google Scholar]
  • 72.Yang Q, Niu Q, Zhou Y, Liu Y, Xu H, Gu W, et al. Incidence of cerebral hemorrhage in the Changsha community: A prospective study from 1986 to 2000. Cerebrovasc Dis. 2004;17:303–313. doi: 10.1159/000077341 [DOI] [PubMed] [Google Scholar]
  • 73.Jiang H, Pan D. Influencing factors of prognosis Acute haemorrhagic stroke. Chin J Geriatr Heart Brain Vessel Dis. 2011;13:79. [Google Scholar]
  • 74.Wang Y, Ji H, Tong Y, Zhang Z. Prognostic value of serum 25-hydroxyvitamin D in patients with stroke. Neurochem Res. 2014;39:1332–1337. doi: 10.1007/s11064-014-1316-0 [DOI] [PubMed] [Google Scholar]
  • 75.Dong X, Tao D, Wang Y, Cao H, Xu Y, Wang Q. Plasma copeptin levels in Chinese patients with acute ischemic stroke: a preliminary study. Neurol Sci. 2013;34:1591–1595. doi: 10.1007/s10072-013-1291-2 [DOI] [PubMed] [Google Scholar]
  • 76.Zhang J, Yin C, Zhang Y, Zhao L, Fu H, Feng J. Plasma copeptin and long-term outcomes in acute ischemic stroke. Acta Neurol Scand. 2013;128:372–380. doi: 10.1111/ane.12132 [DOI] [PubMed] [Google Scholar]
  • 77.Xie S, Lu L, Liu L, Bi G, Zheng L. Progranulin and short-term outcome in patients with acute ischaemic stroke. Eur J Neurol. 2016;23:648–655. doi: 10.1111/ene.12920 [DOI] [PubMed] [Google Scholar]
  • 78.Du G, Zheng B, Wang Q, Yang C. Comparison of clinical outcomes in elderly stroke patients with LAA and those with cardiogenic embolism-induced LVO. Chin J Geriatr Heart BrainVessel Dis. 2018;20:42–45. [Google Scholar]
  • 79.Zhang X, Chen Y, Ge L, Ge Z, Zhang Y. Features of stroke in Chinese diabetes patients: a hospital-based study. J Int Med Res. 2007;35:540–546. doi: 10.1177/147323000703500414 [DOI] [PubMed] [Google Scholar]
  • 80.Tao C, Hu X, Wang J, Ma J, Li H, You C. Admission neutrophil count and neutrophil to lymphocyte ratio predict 90-day outcome in intracerebral hemorrhage. Biomark Med. 2017;11:33–42. doi: 10.2217/bmm-2016-0187 [DOI] [PubMed] [Google Scholar]
  • 81.He D, Zhang Y, Zhang B, Jian W, Deng X, Yang Y, et al. Serum Procalcitonin Levels are Associated with Clinical Outcome in Intracerebral Hemorrhage. Cell Mol Neurobiol. 2018;38:727–733. doi: 10.1007/s10571-017-0538-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Li W, Liu M, Wu B, Liu H, Wang L, Tan S. Serum lipid levels and 3-month prognosis in Chinese patients with acute stroke. Adv Ther. 2008;25:329–341. doi: 10.1007/s12325-008-0045-7 [DOI] [PubMed] [Google Scholar]
  • 83.Wu H, Jia Q, Liu G, Liu L, Pu Y, Zhao X, et al. Decreased uric acid levels correlate with poor outcomes in acute ischemic stroke patients, but not in cerebral hemorrhage patients. J Stroke Cerebrovasc Dis. 2014;23:469–475. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.007 [DOI] [PubMed] [Google Scholar]
  • 84.Tu W, Ma G, Ni Y, Hu X, Luo D, Zeng X, et al. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke. Neurology. 2017;88:1899–1905. doi: 10.1212/WNL.0000000000003937 [DOI] [PubMed] [Google Scholar]
  • 85.Tu W, Qiu H, Zhang Y, Cao J, Wang H, Zhao J, et al. Lower serum retinoic acid level for prediction of higher risk of mortality in ischemic stroke. Neurology. 2019;92:E1678–E1687. doi: 10.1212/WNL.0000000000007261 [DOI] [PubMed] [Google Scholar]
  • 86.Zhang L, Yang J, Hong Z, Yuan G, Zhou B, Zhao L, et al. Proportion of different subtypes of stroke in China. Stroke. 2003;34:2091–2096. doi: 10.1161/01.STR.0000087149.42294.8C [DOI] [PubMed] [Google Scholar]
  • 87.Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, et al. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet neurol. 2019;18:439–458. doi: 10.1016/S1474-4422(19)30034-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Groves RM. Nonresponse rates and nonresponse bias in household surveys. Public Opin Q. 2006;70:646–675. [Google Scholar]
  • 89.Sf Du, Lü B Wang Zh, Zhai F. Transition of dietary pattern in China. Wei Sheng Yan Jiu. 2001;30(4):221–225. [PubMed] [Google Scholar]
  • 90.Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, et al. Incidence and trends of stroke and its subtypes in China: results from three large cities. Stroke. 2006;37(1):63–68. doi: 10.1161/01.STR.0000194955.34820.78 [DOI] [PubMed] [Google Scholar]
  • 91.Li Z, Jiang Y, Li H, Xian Y, Wang Y. China’s response to the rising stroke burden. BMJ. 2019;364:l879. doi: 10.1136/bmj.l879 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Wang W, Wang D, Liu H, Sun H, Jiang B, Ru X, et al. Trend of declining stroke mortality in China: reasons and analysis. Stroke Vasc Neurol. 2017;2:132–139. doi: 10.1136/svn-2017-000098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Wei JW, Wang J, Huang Y, Liu M, Wu Y, Wong LKS, et al. Secondary Prevention of Ischemic Stroke in Urban China. Stroke. 2010;41:967–974. doi: 10.1161/STROKEAHA.109.571463 [DOI] [PubMed] [Google Scholar]
  • 94.Xu J, Zhao M, Vrosgou A, Yu NCW, Liu C, Zhang H, et al. Barriers to medication adherence in a rural-urban dual economy: a multi-stakeholder qualitative study. BMC Health Serv Res. 2021;21(1):799. doi: 10.1186/s12913-021-06789-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Bettger JP, Li Z, Xian Y, Liu L, Zhao X, Li H, et al. Assessment and provision of rehabilitation among patients hospitalized with acute ischemic stroke in China: Findings from the China National Stroke Registry II. Int J Stroke. 2017;12(3):254–263. doi: 10.1177/1747493017701945 [DOI] [PubMed] [Google Scholar]
  • 96.Asakawa T, Zong L, Wang L, Xia Y, Namba H. Unmet challenges for rehabilitation after stroke in China. The Lancet. 2017;390(10090):121–122. doi: 10.1016/S0140-6736(17)31584-2 [DOI] [PubMed] [Google Scholar]
  • 97.Qiu X, Sit JWH, Koo FK. The influence of Chinese culture on family caregivers of stroke survivors: A qualitative study. J Clin Nurs. 2018;27(1–2):e309–e319. doi: 10.1111/jocn.13947 [DOI] [PubMed] [Google Scholar]
  • 98.Sit JWH, Wong TKS, Clinton M, Li LSW, Fong Y-m. Stroke care in the home: the impact of social support on the general health of family caregivers. J Clin Nurs. 2004;13(7):816–824. doi: 10.1111/j.1365-2702.2004.00943.x [DOI] [PubMed] [Google Scholar]
  • 99.Tsai C, Thomas B, Sudlow MLC. Epidemiology of stroke and its subtypes in Chinese vs white populations: A systematic review. Neurology. 2013;81:264–272. doi: 10.1212/WNL.0b013e31829bfde3 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Miguel A Barboza

27 Sep 2021

PONE-D-21-22996Pooled incidence and case-fatality of acute stroke in China: a systematic review and meta-analysisPLOS ONE

Dear Dr. He,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

 A few minor suggestions are already missing, find attached the reviewer comments (which could be suitable for the discussion section when justifying your findings); the manuscript improved in terms of the quality of the analysis, and most of the changes/suggestions were addressed.  Please submit your revised manuscript by Nov 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Miguel A. Barboza, MD, MSc

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: � The systematic review and meta-analysis is very well structured, ideas are clear and the writing is concise. I congratulate the author/authors for this. The review of literature is comprehensive and the importance of the research is very well discussed as far as applied perspective and theoretical aspect is concerned. The author/ authors have done good reference to the theoretical fundament for the article.

� The tables, figures are helpful to understand the content of the paper.

� I will like to suggest few points:

1. The article mentions that there is varying incidence of acute stroke in the the four economic regions with the lowest rates detected in the east coast. This could be because of better healthcare facilities and affordability of population in that region. Increased trends over time in the incidence of TS and IS were observed possibly because of major changes in lifestyle over a period of 4 decades, A three-to-twelve-month fatality following IS increased over time. This could be because of poor rehabilitation, affordability, inadequate follow up and non-compliance with the treatment. This could be because of poor counselling and information to the caregivers about the post stroke care of the patient.

2. This meta-analysis will help in:

a. Reinforcement and concretisation of policies by the policymakers in China to plan according to social and cultural variations of their four economic regions.

b. Planning strategies for primordial, primary and secondary prevention and allocating funds accordingly for infrastructural development.

c. Employing trained workforce in the field of neurosciences for stroke population. Also, developing multi-task force which will comprise of trained healthcare workers, community leaders, private and government sectors and other non-governmental organisations in China.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr.(Professor). Man Mohan Mehndiratta

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jun 27;17(6):e0270554. doi: 10.1371/journal.pone.0270554.r002

Author response to Decision Letter 0


19 Oct 2021

20th October 2021

Dear Prof. Miguel A. Barboza,

Re: PONE-D-21-22996 – “Pooled incidence and case-fatality of acute stroke in China: a systematic review and meta-analysis”

Thank you for the opportunity to revise the manuscript which the reviewer described as “well structured” and “comprehensive” highlighting the importance of our research project as being “very well discussed”. In line with the editor’s and reviewer’s comments, as requested, we have responded on a point-by-point basis and have changed the manuscript accordingly.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: The manuscript has been modified against these style requirements.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: As suggested, the reference list has been checked ensuring it is complete and correct. Retracted papers have not been cited in the manuscript.

The reference list has been revised to support the added points in the discussion as suggested by the reviewer. The reference of the accepted protocol of this study has also been added.

Response to reviewers’ comments

Reviewer #1:

Comment 1:

The systematic review and meta-analysis is very well structured, ideas are clear and the writing is concise. I congratulate the author/authors for this. The review of literature is comprehensive and the importance of the research is very well discussed as far as applied perspective and theoretical aspect is concerned. The author/ authors have done good reference to the theoretical fundament for the article.

The tables, figures are helpful to understand the content of the paper.

Response: We thank the Reviewer for these positive comments.

Comment 2:

1. The article mentions that there is varying incidence of acute stroke in the the four economic regions with the lowest rates detected in the east coast. This could be because of better healthcare facilities and affordability of population in that region. Increased trends over time in the incidence of TS and IS were observed possibly because of major changes in lifestyle over a period of 4 decades. A three-to-twelve-month fatality following IS increased over time. This could be because of poor rehabilitation, affordability, inadequate follow up and non-compliance with the treatment. This could be because of poor counselling and information to the caregivers about the post stroke care of the patient.

Response: We thank the Reviewer for these insightful comments. Regional differences in stroke incidence in China have been continuously reported, often explained in the literature as a reflection of different prevalence of major risk factors, including hypertension, smoking, drinking and unhealthy diet. The unbalanced economic development in different regions may have impacted the health care system across different regions. Although populations residing in more developed regions (such as the East coast) may be utilizing health care services more than those residing in less developed regions. Following a comprehensive literature search we could not find any literature to support the notion that inequality in health resources distribution may have contributed to regional differences in stroke incidence. Therefore, we prefer to be more conservative when discussing these differences by only emphasizing the different patterns of risk factors across these regions.

As suggested, the possible association between increasing stroke incidence and changing lifestyles is now discussed in the revised manuscript. As mentioned in the original manuscript, improving post-stroke rehabilitation may decrease the three-to-twelve-month fatality following ischaemic stroke (IS). In the revised manuscript we further discussed post stroke rehabilitation and its importance to study outcomes (please see page 19). Affordability is indeed a problem in stroke care in China, which may affect patients’ adherence to secondary stroke prevention medications and access to rehabilitation. The issue of affordability has also been added to this revised manuscript. Non-compliance reflected by nonadherence to medication and insufficient support for the caregivers have similarly been discussed.

It is possible that inadequate follow up could have contributed to increasing three-to-twelve-month fatality following IS but we could not support this statement by published literature and therefore we did not add this point to the revised discussion.

Comment 3

2. This meta-analysis will help in:

a. Reinforcement and concretisation of policies by the policymakers in China to plan according to social and cultural variations of their four economic regions.

b. Planning strategies for primordial, primary and secondary prevention and allocating funds accordingly for infrastructural development.

c. Employing trained workforce in the field of neurosciences for stroke population. Also, developing multi-task force which will comprise of trained healthcare workers, community leaders, private and government sectors and other non-governmental organisations in China.

Response: We thank the Reviewer for these insightful points, which we added to the revised discussion.

Yours sincerely,

Fan He

La Trobe University, Melbourne

Attachment

Submitted filename: Response to reviewers_v6.docx

Decision Letter 1

Miguel A Barboza

25 Nov 2021

PONE-D-21-22996R1Pooled incidence and case-fatality of acute stroke in China: a systematic review and meta-analysisPLOS ONE

Dear Dr. He,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

 There are new suggestions regarding methodology and results section, according to our statistician expert, therefore, I suggest to pay attention to this new comments.

Please submit your revised manuscript by Jan 09 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Miguel A. Barboza, MD, MSc

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I will focus on methods and reporting

Major

1) funnel plots and publication bias tests only make sense in the presence of an intervention, they are meaningless for incidence rates and in this context.

2) Language corrections are needed.

3) Some justification is needed on the 1990 time limit.

4) Meta-regression is a stab in the dark usually and is underpowered to detect anything but massive associations (effectively a regression with X observations, where X is the number of available studies). You should discuss this as a major limitation. Even with 60 or 80 studies, it can provide little insight.

5) Report the confidence intervals for I^2 (calculated using heterogi or metaan in Stata) as argued in http://www.ncbi.nlm.nih.gov/pubmed/17974687. A simple formula exists in the seminal 2002 Higgins paper that proposed I^2.

Minor

1) Add some more info on the methods section in the abstract, was heterogeneity assessed, publication bias assessed (if relevant) etc.

2) Clarify that the estimates were back transformed for the forest plots

3) The axis titles on the forest plots are not clear, reported as percentages when they are supposed to be rates. Currently the methods section and the graphs are not in agreement.

4) How was the random-effect model implemented, i.e. how was heterogeneity estimated? There are numerous ways to do so. Did they use the standard DerSimonian-Laird method? If so, please state so. Also there are better performing methods, for example please see https://www.ncbi.nlm.nih.gov/pubmed/28815652

5) What Stata commands were used? Again this relates to the point about the methods and the graphs.

6) Clarify the variables included in the meta regression in the methods section.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jun 27;17(6):e0270554. doi: 10.1371/journal.pone.0270554.r004

Author response to Decision Letter 1


24 Dec 2021

24th December 2021

Dear Prof. Miguel A. Barboza,

Re: PONE-D-21-22996R1 – “Pooled incidence and case-fatality of acute stroke in Mainland China, Hong Kong, and Macao: a systematic review and meta-analysis”

Thank you for the opportunity to revise the manuscript. In line with the editor’s and reviewer’s comments, as requested, we have responded on a point-by-point basis and have changed the manuscript accordingly.

Journal Requirements:

1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: As suggested, the reference list has been checked ensuring it is complete and correct. Retracted papers have not been cited in the manuscript.

We slightly revised the title of this manuscript making it consistent with the protocol paper that is currently in print.

• He F, Blackberry I, Yao L, Xie H, Mnatzaganian G. Geographic Disparities in Pooled Stroke Incidence and Case Fatality in Mainland China, Hong Kong and Macao: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc. Forthcoming. doi:10.2196/32566

Response to reviewers’ comments

Comment 1:

If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

No Response

Comment 2:

2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

Response: We have responded to this comment. Please find our reasoning and responses detailed in the subsequent reviewer’s comments below

Comment 3

Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Response: We thank the Reviewer for this positive comment.

Comment 4

Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Response: We thank the Reviewer for this positive comment.

Comment 5

Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

Response: This manuscript has been edited by a native English speaker.

Comment 6

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I will focus on methods and reporting

No Response

Major

1) funnel plots and publication bias tests only make sense in the presence of an intervention, they are meaningless for incidence rates and in this context.

Response: We respectfully disagree with the reviewer.

We used funnel plots together with Egger’s tests to investigate whether the studies included in the systematic review had a biased representation of higher or lower incidences; that is, publication bias.

One criticism of meta-analyses is that often the available studies may not be representative of all studies addressing the research question. Publication bias refers to the claim that studies with statistically significant results are more likely to be published than studies without. Publication bias can occur in other instances besides trial study designs (Copper et al 2009). An example of a possible scenario is when a hospital director opposes the publication of results that show very high fatality rates. The funnel plot and Egger’s tests investigated whether our findings on between study heterogeneity was due to publication bias.

• Cooper H et al. The handbook of research synthesis and meta-analysis. 2nd edition. Russel Sage Foundation. New York. 2009

Running funnel plots with Egger’s test or other tests that investigate asymmetry is very commonly done in systematic reviews in observational incidence studies. We refer the reviewer to the following publications, which are a few of many that followed this very acceptable statistical method.

• Megan R et al. Systematic review and meta-analysis of the incidence rate of Takayasu arthritis. Rheumatology, 2020; 60(11):4982-4990.

• Makin SDJ, et al. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry. 2013; 84:893-900.

• Hackett ML, et al. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014, 9:1017-25.

• Li M et al. Hyperuricemia and risk of stroke: A systematic review and meta-analysis of prospective studies. Atherosclerosis, 2014:265-270.

• Taylor M et al. Longevity of complete dentures: a systematic review and meta-analysis. J Prosthetic Dentistry. 2021; 125:611-617

• Fasugba O et al. Ciprofloxacin resistance in community- and hospital acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis. 2015, 15:545.

• Qin B, et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2015;74:1983-1989.

• Meng K, et al. "Incidence of venous thromboembolism during pregnancy and the puerperium: a systematic review and meta-analysis." The Journal of Maternal-Fetal & Neonatal Medicine 28.3 (2015): 245-253.

2) Language corrections are needed.

Response: This manuscript has been edited by a native English speaker.

3) Some justification is needed on the 1990 time limit.

Response: The decision to exclude studies published before 1991 was made to better capture studies that followed similar diagnostic criteria. Before 1991, clinicians would have diagnosed stroke without brain imaging technologies which could have resulted in the inclusion of false positive cases. The restriction to 1991 onwards aimed to decrease false positives and to increase the validity of included cases. We have added a clarification in the revised manuscript.

4) Meta-regression is a stab in the dark usually and is underpowered to detect anything but massive associations (effectively a regression with X observations, where X is the number of available studies). You should discuss this as a major limitation. Even with 60 or 80 studies, it can provide little insight.

Response: Meta regression offers a systematic approach to explain sources of wide variation in reported findings. In our incidence studies, no heterogeneity was detected and, therefore, there was no need to conduct further analyses. However, in the case-fatality analyses, we conducted meta regression to explain between study variances based on the available study variables.

Meta-regression is an extension to subgroup analyses that allows the effect of continuous, as well as categorical characteristics to be investigated, and in principle allows the effects of multiple factors to be investigated simultaneously (although this is rarely possible due to inadequate numbers of studies) (Thompson 2002). According to scientific literature, meta-regression should generally not be considered when there are fewer than 10 to 15 studies in a meta-analysis. Our case-fatality analysis included 39 studies.

1. Cochrane handbook for systematic reviews of interventions. https://training.cochrane.org/handbook/current

2. Higgins JPT, et al. Measuring inconsistency in meta-analysis. BMJ Clinical Research. 327:557-60.

3. Thompson SG, et al. How should meta-regression analyses be undertaken and interpreted? Statistics in Medicine. 2002; 21:1559-1573

4. https://handbook-5-1.cochrane.org/chapter_9/9_6_4_meta_regression.htm

We acknowledge that exploring all sources of heterogeneity is limited as there are many unknown variables that cannot be accounted for. This is always true in all systematic reviews (Copper et al, 2009). Furthermore, the limited number of included studies in the meta-regression add uncertainty in the true sources of heterogeneity. These limitations have been added to the revised manuscript.

5) Report the confidence intervals for I^2 (calculated using heterogi or metaan in Stata) as argued in http://www.ncbi.nlm.nih.gov/pubmed/17974687. A simple formula exists in the seminal 2002 Higgins paper that proposed I^2.

Response: The heterogeneity in case-fatality analyses was very high and statistically significant (p<0.001). As requested, using Borenstein and colleagues methods, we have estimated confidence intervals for the statistic I-squared..

Borenstein M, et al. Introduction to meta-analysis. John Wiley & Sons, Ltd. UK. 2011

Minor

1) Add some more info on the methods section in the abstract, was heterogeneity assessed, publication bias assessed (if relevant) etc.

Response: As suggested, we have revised the abstract to include this.

2) Clarify that the estimates were back transformed for the forest plots

Response: The methods we used are stated in the manuscript: “Using the Exact method, the incidence rates of disease were expressed as Poisson means divided by time at risk. The log incidence rates together with their corresponding log standard errors, stratified by the four economic regions, were meta-analysed using DerSimonian and Laird random effects model. Random effects models were also used to estimate the pooled case fatality estimates”.

3) The axis titles on the forest plots are not clear, reported as percentages when they are supposed to be rates. Currently the methods section and the graphs are not in agreement.

Response: As shown in Figure 2, the title of axis is incidence rate. While, in Figures 4 and 5, the title of axis is proportion.

4) How was the random-effect model implemented, i.e. how was heterogeneity estimated? There are numerous ways to do so. Did they use the standard DerSimonian-Laird method? If so, please state so. Also there are better performing methods, for example please see https://www.ncbi.nlm.nih.gov/pubmed/28815652

Response: This has been stated in the section of “Statistical analysis”: “The log incidence rates together with their corresponding log standard errors, stratified by the four economic regions, were meta-analysed using DerSimonian and Laird random effects model. Random effects models were also used to estimate the pooled case fatality estimates.” We have revised the forest plots showing the case fatalities – now including the weights that were generated by the random effect model.

5) What Stata commands were used? Again this relates to the point about the methods and the graphs.

Response: We used metan and metaprop Stata commands for incidence and case fatality studies, respectively. We have added this clarification in Methods.

6) Clarify the variables included in the meta regression in the methods section.

Response: The meta-regression models included risk of bias, study setting (community or hospital), follow-up time, smoking status, age, sex, and severity of stroke. This has been clarified in the methods section.

Yours sincerely,

Fan He

La Trobe University, Melbourne

Attachment

Submitted filename: Response to reviewer 2_v2_final.docx

Decision Letter 2

Salvatore De Rosa

14 Jun 2022

Pooled incidence and case-fatality of acute stroke in Mainland China, Hong Kong, and Macao: a systematic review and meta-analysis

PONE-D-21-22996R2

Dear Dr. He,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Salvatore De Rosa

Academic Editor

PLOS ONE

Acceptance letter

Salvatore De Rosa

17 Jun 2022

PONE-D-21-22996R2

Pooled incidence and case-fatality of acute stroke in Mainland China, Hong Kong, and Macao: a systematic review and meta-analysis

Dear Dr. He:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Salvatore De Rosa

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA checklist.

    (DOCX)

    S1 Table. Search strategy.

    (DOCX)

    S2 Table. Risk of bias assessments.

    (DOCX)

    S1 Fig. Pooled estimates of total stroke incidence in east coast China and other regions.

    (TIFF)

    S2 Fig. Pooled estimates of ischaemic stroke incidence in east coast China and other regions.

    (TIFF)

    S3 Fig. Pooled estimates of haemorrhagic stroke incidence in east coast China and other regions.

    (TIFF)

    S4 Fig. Funnel plots and Egger’s tests.

    (TIFF)

    S5 Fig. Sensitivity analysis for total stroke incidence.

    (TIFF)

    S6 Fig. Total stroke incidence rate by sub-group analysis.

    (TIFF)

    S7 Fig. Pooled estimates of total stroke incidence in map of China.

    (TIFF)

    S8 Fig. Total stroke incidence by length of follow up.

    (TIFF)

    S9 Fig. Pooled estimates of ischaemic stroke incidence by the four Chinese economical regions.

    (TIFF)

    S10 Fig. Pooled estimates of haemorrhagic stroke incidence by the four Chinese economical regions.

    (TIFF)

    S1 File. Included Chinese papers and translations.

    (DOCX)

    Attachment

    Submitted filename: Response to reviewers_v6.docx

    Attachment

    Submitted filename: Response to reviewer 2_v2_final.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES